BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16468237)

  • 1. [High dose therapy with autologous stem cell transplantation in patients with Hodgkin's lymphoma: long-term follow-up in patients treated in one center].
    Trnĕný M; Vacková B; Pytlík R; Cieslar P; Válková V; Gasová Z; Kobylka P; Trnková M; Krejcová H; Klener P
    Cas Lek Cesk; 2006; 145(1):19-24. PubMed ID: 16468237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
    Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
    Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous stem cell transplantation in advanced follicular lymphoma. A single center experience.
    López R; Martino R; Sureda A; Nomdedéu J; Briones J; Martin-Henao G; García J; Brunet S; Sierra J
    Haematologica; 1999 Apr; 84(4):350-5. PubMed ID: 10190950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
    Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
    Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
    Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K
    Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
    Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
    Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
    Tarella C; Cuttica A; Vitolo U; Liberati M; Di Nicola M; Cortelazzo S; Rosato R; Rosanelli C; Di Renzo N; Musso M; Pavone E; Santini G; Pescarollo A; De Crescenzo A; Federico M; Gallamini A; Pregno P; Romano R; Coser P; Gallo E; Boccadoro M; Barbui T; Pileri A; Gianni AM; Levis A
    Cancer; 2003 Jun; 97(11):2748-59. PubMed ID: 12767087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose therapy autologous stem cell transplantation vs conventional therapy for patients with advanced Hodgkin's disease responding to first-line therapy: analysis of clinical characteristics of 51 patients enrolled in the HD01 protocol. EBMT/ANZLG/Intergroup HD01 Trial.
    Federico M; Clò V; Carella AM
    Leukemia; 1996 Jun; 10 Suppl 2():s69-71. PubMed ID: 8649056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.
    Federico M; Bellei M; Brice P; Brugiatelli M; Nagler A; Gisselbrecht C; Moretti L; Colombat P; Luminari S; Fabbiano F; Di Renzo N; Goldstone A; Carella AM;
    J Clin Oncol; 2003 Jun; 21(12):2320-5. PubMed ID: 12805333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
    Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
    J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
    Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
    Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS].
    Fröhlich B; Ahrens S; Burdach S; Klingebiel T; Ladenstein R; Paulussen M; Zoubek A; Jürgens H
    Klin Padiatr; 1999; 211(4):284-90. PubMed ID: 10472563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.
    Ahn JS; Yang DH; Jung SH; Chae YS; Sohn SK; Yhim HY; Kwak JY; Lee SR; Kim YK; Kim HJ; Lee JJ
    Ann Hematol; 2013 Jun; 92(6):789-97. PubMed ID: 23358616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Sweetenham JW; Taghipour G; Milligan D; Blystad AK; Caballero D; Fassas A; Goldstone AH
    Bone Marrow Transplant; 1997 Nov; 20(9):745-52. PubMed ID: 9384476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy and autologous stem cell transplantation for Hodgkin's lymphoma in the kingdom of Saudi Arabia: King Faisal specialist hospital and research center experience.
    Akhtar S; Abdelsalam M; El Weshi A; Al Husseini H; Janabi I; Rahal M; Maghfoor I
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S37-S40. PubMed ID: 18724297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
    Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I
    Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.